Rapid HIV-RNA decline following addition of raltegravir and tenofovir to ongoing highly active antiretroviral therapy in a woman presenting with high-level HIV viraemia at week 38 of pregnancy

J Antimicrob Chemother. 2010 Sep;65(9):2050-2. doi: 10.1093/jac/dkq264. Epub 2010 Jul 14.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / administration & dosage
  • Adenine / analogs & derivatives*
  • Anti-HIV Agents / administration & dosage*
  • Antiretroviral Therapy, Highly Active / methods*
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • Humans
  • Organophosphonates / administration & dosage*
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Pregnancy Complications, Infectious / virology
  • Pyrrolidinones / administration & dosage*
  • RNA, Viral / blood*
  • Raltegravir Potassium
  • Tenofovir
  • Viral Load
  • Viremia

Substances

  • Anti-HIV Agents
  • Organophosphonates
  • Pyrrolidinones
  • RNA, Viral
  • Raltegravir Potassium
  • Tenofovir
  • Adenine